Study of Anlotinib in Patients With Esophageal Squamous Cell Carcinoma (ALTER1102)

Anlotinib Hydrochloride Capsules Combined With TQB2450 Injection in Esophageal Squamous Cell Carcinoma Patients

NCT05252078 ·Status: RECRUITING ·Phase: PHASE2

Utidelone and Anlotinib in Advanced Recurrent Metastatic Esophageal Cancer

NCT05866510 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib Combined With PD-1 Inhibitors for Advanced/Metastatic Esophageal Cancer

NCT04984096 ·Status: UNKNOWN

A Study of Neoadjuvant Therapy for the Treatment of Patients With Locally Advanced Esophageal Squamous Cell Carcinoma

NCT06354530 ·Status: RECRUITING ·Phase: PHASE2/PHASE3

A Study of Simmitinib Plus Irinotecan in Advanced Esophageal Squamous Cell Carcinoma

NCT06512428 ·Status: RECRUITING ·Phase: PHASE2

Neoadjuvant Therapy of Anlotinib Combined With Toripalimab and Chemotherapy for Resectable Esophageal Carcinoma

NCT05996484 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

A Study of Atezolizumab Plus Tiragolumab in Combination With Paclitaxel and Cisplatin Compared With Paclitaxel and Cisplatin as First-Line Treatment in Participants With Unresectable Locally Advanced, Unresectable Recurrent, or Metastatic Esophageal Carcinoma

NCT04540211 ·Status: COMPLETED ·Phase: PHASE3

A Single-center, Multicohort, Phase II Clinical Study Evaluating the Combination Therapy of Sacituzumab Tirumotecan in Patients With Unresectable, Locally Advanced, Recurrent, or Metastatic Esophageal Squamous Cell Carcinoma

NCT07128693 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Anrotenib Plus Toripalimab Versus Toripalimab in Patients With Advanced Esophageal Squamous Cell Carcinoma

NCT04229849 ·Status: UNKNOWN ·Phase: PHASE2

Anlotinib for Esophageal Cancer (AFEC)

NCT04966611 ·Status: UNKNOWN

A Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 Combination Therapy or Monotherapy in Patients With Advanced ESCC

NCT05221658 ·Status: UNKNOWN ·Phase: PHASE2

TC Plus PD-1 Inhibitors Combined With Anlotinib for Advanced Advanced Esophageal Cancer

NCT04471480 ·Status: UNKNOWN ·Phase: NA

Study of Larotinib in Unresectable Advanced or Recurrent Esophageal Cancer

NCT04415853 ·Status: RECRUITING ·Phase: PHASE3

Apatinib for Esophageal Squamous Cell Cancer After the Failure of Standard Treatment

NCT02976896 ·Status: COMPLETED ·Phase: PHASE2

A Study of CS1001 in Subjects With Esophageal Squamous Cell Carcinoma

NCT04187352 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma

NCT06426797 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2

Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer

NCT05322499 ·Status: UNKNOWN ·Phase: PHASE2

Efficacy and Safety of Penpulimab Combined With Anlotinib and Chemotherapy

NCT06586242 ·Status: RECRUITING ·Phase: PHASE2

Study of IBI308 With Advanced/Metastatic Esophageal Squamous Cell Carcinoma After Failure of First-line Treatment

NCT03116152 ·Status: COMPLETED ·Phase: PHASE2

Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer

NCT02569242 ·Status: COMPLETED ·Phase: PHASE3

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma

NCT04390958 ·Status: UNKNOWN ·Phase: PHASE2

Second-line Cabozantinib and Atezolizumab in Patients With Recurrent or Metastatic Esophageal Squamous Cell Carcinoma

NCT05007613 ·Status: COMPLETED ·Phase: PHASE2

Neoadjuvant Immunotherapy Combined With Chemotherapy in Patients With Locally Advanced ESCC

NCT05807542 ·Status: COMPLETED ·Phase: PHASE2

A Study of Trifluridine/Tipiracil Combined With Anlotinib as Second-line Treatment for Recurrent and Metastatic Esophageal Squamous Cell Carcinoma

NCT07142421 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2

Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification

NCT04880811 ·Status: UNKNOWN ·Phase: PHASE2